Improve diagnostic yield and value
Hereditary peripheral neuropathies are a diverse group of disorders with varying presentations and genetic causes. Although these disorders can sometimes be categorized by extent of weakness, sensory involvement, and/or autonomic involvements, overlapping phenotypes present difficulties in distinguishing inherited disorders from acquired or idiopathic forms of the illness.
Previous testing approaches required evaluating a large array of etiologies for possible acquired causes while simultaneously guessing which individual gene might be responsible, which resulted in low diagnostic yield and high costs. Increasingly, a comprehensive approach using next-generation sequencing (NGS) has proven to enable greater value in testing.
Mayo Clinic Laboratories’ testing is backed by a multidisciplinary team of clinical peripheral neuropathy experts, laboratory scientists, and genetic counselors to provide the highest standard for mutation detection.
Using targeted capture techniques and unique reporting methods, our focused approach allows for optimal mutation detection. This process eliminates the risk of false negative results compared to whole-exome sequencing and other capture techniques. This provides physicians with the confidence that disease-specific mutations have not been missed.
In addition, our custom gene ordering tool allows physicians to choose what genes they want and build custom panels to fit each patient’s unique needs.
Increasing Diagnostic Yield in Hereditary Peripheral Neuropathy
This webinar offers an educational overview of the large category of peripheral neuropathies, with a focus on identifying hereditary neuropathies. Various testing platforms and their strengths and weaknesses will be discussed in diagnosing affected patients. Cases will be used to illustrate the points.
Learn more about how to order these tests at your institution.